

## Anjana Pillai, MD, FAASLD, FAST, FACG

University of Chicago Medicine  
Section of Gastroenterology, Hepatology & Nutrition  
5841 S. Maryland Ave, MC 7120  
Chicago, IL 60637  
cell: (786) 218-0107  
email: [apillai1@medicine.bsd.uchicago.edu](mailto:apillai1@medicine.bsd.uchicago.edu)

### ACADEMIC APPOINTMENTS

2008-2009 Clinical Instructor, Northwestern Memorial Hospital  
2009-2012 Assistant Professor of Medicine, Loyola University Medical Center  
2012-2016 Assistant Professor of Medicine and Surgery, Emory University Hospital  
2016-present Associate Professor of Medicine, University of Chicago Medicine  
2017-present Associate Member, University of Chicago Comprehensive Cancer Center

### LEADERSHIP

2013-2016 Medical Director, Liver Tumor Program, Emory University Hospital  
2014-2015 Associate Program Director, Transplant Hepatology Fellowship, Emory University Hospital  
2014-2016 Co-director, MS4 Elective in Transplant Medicine, Emory University Hospital  
2015-2016 Program Director, Transplant Hepatology Fellowship, Emory University Hospital  
2016-present Medical Director, Liver Tumor Program, University of Chicago Medicine  
2016-2020 Associate Program Director, Gastroenterology Fellowship, University of Chicago Medicine  
2018-present Director of Liver Section, Clinical Pathophysiology and Therapeutics for MS2, University of Chicago Medicine  
2019-present Medical Director, Adult Living Donor Liver Transplantation, University of Chicago Medicine  
2020-present Program Director, Transplant Hepatology Fellowship, University of Chicago Medicine

### ACADEMIC TRAINING

1995-1998 Bachelor of Science, University of Miami, Coral Gables, FL  
1998-2002 Doctor of Medicine, University of Miami, Miller School of Medicine, Miami, FL  
2002-2005 Residency, Internal Medicine, University of Illinois Medical Center, Chicago IL  
2005-2008 Fellow, Gastroenterology, Cleveland Clinic, Cleveland, OH  
2008-2009 Fellow, Transplant Hepatology, Northwestern Memorial Hospital, Chicago, IL

### HONORS, PRIZES AND AWARDS

1995-1998 Henry King Stanford Academic Scholarship, University of Miami  
1995-1998 Dean's List, University of Miami  
1995-1998 Cum Laude, University of Miami  
1996-2002 Medical Scholars Program, 7-year BS/MD Combined Honors Program in Medicine, University of Miami School of Medicine  
2007-2008 Chief Fellow, Cleveland Clinic, Cleveland, OH

2008 Poster of Distinction, European Association for the Study of the Liver, Milan, Italy  
 2010 MAGIS Award for Excellence in Patient Care, Loyola University Medical Center  
 2011 ACG/AztraZeneca Senior Fellow Award, Oral presentation, senior author, American College of Gastroenterology annual meeting, Washington DC  
 2011 ACG/Naomi Nakao Gender Based Research Award, Poster presentation, American College of Gastroenterology annual meeting, Washington DC  
 2019 Gastroenterology Fellow Teaching and Mentorship Award, University of Chicago Medicine  
 2020 Fellow, American Association for the Study of Liver Diseases  
 2021 Fellow, American Society of Transplantation  
 2021 Fellow, American College of Gastroenterology

**LICENSING AND BOARD CERTIFICATION**

2004 Illinois  
 2005 Ohio  
 2005-2015 Internal Medicine, American Board of Internal Medicine  
 2008, 2018 Gastroenterology and Hepatology, American Board of Internal Medicine  
 2010 Transplant Hepatology, American Board of Internal Medicine  
 2012 Georgia

**PROFESSIONAL SOCIETIES**

2005-present American Association for the Study of Liver Diseases (AASLD)  
 2005-present American College of Gastroenterology (ACG), Member  
 2005-2008, 2019-present American Gastroenterological Association (AGA)  
 2008-present American Society of Transplantation (AST), Member  
 2009-present American Association of Physicians of Indian Origin (AAPI), Member  
 2015-present American Medical Women’s Association (AMWA), Member  
 2018-current Women in Transplantation, Pillar I Committee Member (since 2020)

**CLINICAL RESEARCH EXPERIENCE**

**Closed to Accrual:**

Role: Institutional PI, Loyola University Medical Center

1. Protocol Number: C1FN-003, REACH SVR registry – Observational Prospective Registry of the efficacy, safety and adherence to therapy of Infigen (Interferon Alfacon 1) in patients chronically infected with hepatic C virus, Sponsored by Three Rivers Pharmaceuticals, 2009
2. Protocol Number: ANA598-505, A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of ANA598 Administered with Pegylated Interferon and Ribavirin in Genotype 1 Patients with Chronic Hepatitis C Infection, Sponsored by Anadys Pharmaceuticals, 2010
3. Protocol Number: OT-1001, A multi-center, randomized, placebo controlled, double blind study to confirm the reversal of hepatorenal syndrome type I with Lucassin® (Terlipressin), Reverse Trial, Sponsored by Ikaria Therapeutics LLC, 2012
4. Protocol Number: 156-08-275, A phase 3b, multi-center, randomized, single-blind, parallel group study of the effects of titrated oral SAMSCA (tolvaptan) 15, 20 or 60 QD compared to placebo plus fluid restriction on length of hospital stay and symptoms in subjects hospitalized with dilutional hyponatremia, Sponsored by Otsuka America Pharmaceutical, Inc., 2012
5. Protocol Number: 156-10-292, An observational prospective registry to identify demographic and clinical characteristics of patients hospitalized with euvolemic and hypervolemic hyponatremia and

assess the comparative effectiveness of available treatments and the impact of resource utilization, Sponsored by Otsuka America Pharmaceutical, Inc., 2012

Role: Institutional PI, Emory University Hospital

6. Protocol Number: 00032504, Entecavir Utilization, Management and Efficacy in the United States: A multi-center Study (ENUMERATE study); Observational, retrospective, multicenter chart review, Sponsored by Asian Health Foundation and Gilead Sciences, 2012
7. Protocol Number: 00000528-16, A Phase 3b, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Ledipasvir/Sofosbuvir, With or Without Ribavirin, in HCV Infected Subjects Who Have Failed Prior Treatment With Sofosbuvir-based Therapies, Sponsored by Gilead Sciences, 2015

Role: Institutional PI, University of Chicago Medicine

8. UH3 TR000884-05 -Extracellular non-coding RNA Markers of hepatocellular carcinoma, Sponsored by National Center for Advancing Translational Sciences (NCATS) and the Office of the Director(NIH). 8/2016-7/2019
9. Blood Sample Collection to Evaluate Biomarkers for Hepatocellular Carcinoma, Sponsored by Exact sciences, 2019- July 2020

**Open, enrolling patients:**

Role: Institutional PI, University of Chicago Medicine

10. Protocol Number: 17-0129A, 5 year Longitudinal Observational Study of the Natural History and Management of Patients with Hepatocellular Carcinoma, sponsored by TARGET study group, 2017
11. A Multi-Centre, Randomised, Open-Label, Phase 2 Study to Assess the Safety, Tolerability and Efficacy of Fimaporfin-Induced Photochemical Internalisation of Gemcitabine Complemented by Gemcitabine/Cisplatin Chemotherapy Versus Gemcitabine/Cisplatin Alone in Patients With Inoperable Cholangiocarcinoma, Sponsored by PCI Biotech, 2021

**SCHOLARSHIP**

Peer-reviewed publications in the primary literature, exclusive of abstracts:

1. **Pillai A**, Nelson R. Probiotics for Clostridium difficile-associated colitis in adults. Cochrane Database of Systematic Reviews 2008 Jan, Issue 1.
2. Hanouneh I, Feldstein A, Lopez R, Yerian L, **Pillai A**, Zein CO, Zein NN. Clinical significance of metabolic syndrome in the setting of chronic HCV infection. Clin Gastroenterol and Hepatol 2008 May; 6(5): 584-9.
3. **Pillai AA**, Lee V, Rinella M, Levitsky J. Factors associated with sustained virologic response in liver transplant recipients with recurrent hepatitis C. Transplant Proc. 2010 Nov; 42(9): 3647-51.
4. Singal AG, **Pillai A**, Tiro, J. Early Detection, Curative Treatment and Survival Rates for HCC Surveillance in Patients with Cirrhosis: A Meta-analysis. PLoS Med. 2014 April: 11(4).
5. Huprikar S, Danziger-Isakov L, Ahn J, Naugler S, Blumberg E, Avery RK, Koval C, Lease ED, **Pillai A**, et al. Solid Organ Transplantation from Hepatitis B Virus-Positive Donors: Consensus Guidelines for Recipient Management. Am J Transplant. 2015 May; 15(5): 1162-72.

6. Xing M, Webber G, Chen Z, Prajapati H, Chen Z, El-Rayes B, Spivey JR, **Pillai AA**, Kim HS. Preservation of Quality of Life with Doxorubicin Drug Eluting Bead Transarterial Chemoembolization for unresectable Hepatocellular Carcinoma: Longitudinal Prospective Study. *J Gastroenterol Hepatol*. 2015 Jul; 30(7):1167-74.
7. Collins JM, Raphael KL, Terry C, Cartwright EJ, **Pillai A**, Anania FA, Farley MM. Hepatitis B Reactivation During Successful Treatment of Hepatitis C with Sofosbuvir and Simeprevir. *Clin Infect Dis*. 2015 Oct 15; 61(8): 1304-6.
8. **Kathpalia P**, Bhatia A, Robertazzi S, Ahn J, Cohen SM, Sontag S, Luke A, Durazo R, **Pillai AA**. Indwelling Peritoneal Catheters in Patients with Cirrhosis and Refractory Ascites. *Intern Med J*. 2015 Oct; 45(10): 1026-31.
9. Cohen SM, Dholakia A, VanderHeyden TR, **Pillai A**, Ahn J. Outcomes and Safety of Open vs. Laparoscopic Surgery in Patients with Cirrhosis. *J Gastroenterol*. 2015; 1(1): 1001.
10. **Pillai AA**, Wedd J, Norvell JP, Parekh S, Cheng N, Young N, Spivey JR, Ford R. Simeprevir and Sofosbuvir (SMV-SOF) for 12 weeks for the Treatment of Chronic Hepatitis C Genotype 1 Infection: A Real World (Transplant) Hepatology Practice Experience. *Am J of Gastroenterol*. 2016 Feb; 111(2): 250-60.
11. Ahn J, Lim JK, Lee HM, Lok AS, Nguyen M, Pan CQ, Mannalithaa A, Te H, Reddy KR, Trinh H, Chu D, Tran T, Lau D, Leduc T, Min A, Tron L, Bae H, Tran SV, Do S, Hann H, Wong C, Han S, **Pillai AA**, et al. Lower Observed Hepatocellular Carcinoma Incidence in Chronic Hepatitis B Patients Treated with Entecavir: Results of the ENUMERATE Study. *Am J of Gastroenterol*. 2016 Sep; 111(9): 1297-304.
12. **Pillai A**, Maheshwari R, Vora R, Norvell JP, Ford R, Parekh S, Cheng N, Patel A, Young N, Spivey J, Mgbemena O, Wedd J. Treatment of HCV Infection in Post-Liver Transplant Recipients with Ledipasvir and Sofosbuvir without Ribavirin: A Large Single Center Experience. *Aliment Pharmacol Ther*. 2017 Jun;45(11):1427-1432.
13. Spengler E, O'Leary JG, Te HS, Rogal S, **Pillai AA**, Al-Osaimi A, Desai A, Fleming J, Ganger D, Seetharam A, Tsoulfas G, Montenovolo M, Lai JC. Liver Transplantation in the Obese Cirrhotic Patient. *Transplantation*. 2017 Oct; 101(10): 2288-2296.
14. Singal AG, Rich NE, Mehta N, Branch A, **Pillai A**, Hoteir M, Volk M, Odewole M, et al. Direct-Acting Antiviral Therapy is not Associated with HCC Recurrence: A Multicenter North American Cohort Study. *Gastroenterology*. 2019 May; 156(6):1683-1692.
15. Rich NE, Yang JD, Perumalswami P, Alkhouri N, Jackson W, Parikh N, Mehta N, Salgia R...**Pillai A**, et al. Provider Attitudes and Practices for Direct-Acting Antiviral Therapy in Patients with HCC in US. *Clin Gastroenterol Hepatol*. 2019 26. pii: S1542-3565(19)30786-4.
16. Singal AG, Rich NE, Mehta N, Branch A, **Pillai A**, Hoteir M, Volk M, Odewole M, et al. Direct-Acting Antiviral Therapy is Associated with Improved Survival in Patients with a history of HCC: A Multicenter North American Cohort Study. *Gastroenterology*. 2019 Nov; 157(5): 1253-1263.

17. Verna EC, Patel YA, Aggarwal A, Desai AP, Frenette C, **Pillai AA**, Salgia R, Seetharam A, Sharma P, Sherman C, Tsoulfas G, Yao F. Liver Transplantation for Hepatocellular Carcinoma: Management After the Transplant. *Am J Transplant*. 2019 Nov; doi: 10.1111/ajt.15697.
18. Cotter T, Sandikci B, Paul S, Gampa A, Wang J, Te H, **Pillai A**, et al. Liver Transplantation for Alcoholic Hepatitis in the US: Excellent Outcomes with Profound Temporal and Geographic Variaton in Frequency. *Am J Transplant*. 2020 June; doi.org/10.1111/ajt.16143.
19. Kim NJ, Rozenberg-Ben-Dror K, Jacob D, Rich N, Singal AG, Aby E, Yang JD, Nguyen V, **Pillai A**, et al. Provider attitudes toward risk-based hepatocellular carcinoma surveillance in patients with cirrhosis in the US. *Clin Gastroenterol and Hepatol* 2020 Sept, S1542-3565 (20): 31272-6.
20. Badar W, Van Ha T, Zangan S, Navuluri R, **Pillai A**, Baker T, Ahmed, O. Yttrium-90 Radioembolization Therapy for Combined Hepatocellular and Cholangiocarcinoma. *Gastrointest Tumors* 2020 Oct; 7:144-150.
21. Badar W, Van Ha T, Zangan S, Navuluri R, **Pillai A**, Baker T, et al. Safety and efficacy of repeat Y0-radioembolization to the same hepatic arterial territory. *Br J Radiol* 2020; 93: 20200752
22. Cotter TG, Minhem M, Wang J, Peeraphatdit T, Ayoub F, **Pillai A**, Hernandez-Alejandro R, di Sabato D, Charlton M. Living-Donor Liver Transplantation in the United States: Evolution of Frequency, Outcomes, Center Volumes and Factors Associated with Outcomes, *Liver Transpl* 2021 Feb; doi:10.1002/lt.26029
23. Woolen S, Singal A, Davenport M, Troost J, Khalatbari, S, Mittal S, Siddiqui S, Fobar A, Morris J, Odewole M, Tapper E, **Pillai A\***, **Parikh N\*** (*\*co-senior authors*). Patient Preferences for Hepatocellular Carcinoma Surveillance Parameters, *Clin Gastroenterol and Hepatol* 2021 Feb; doi:10.1016/j.cgh.2021.02.024

Reviews, Commentaries, Invited Editorials:

24. **Pillai A**, Levitsky J. Overview of immunosuppression in liver transplantation. *World J Gastroenterol* 2009 Sept; 15(34): 4225-4233.
25. **Pillai A**, Rinella M. Nonalcoholic Fatty Liver Disease: Is bariatric surgery the answer? *Clinics in Liver Disease* 2009 Nov; 13(4): 689-710.
26. **Pillai A**. Management of de novo malignancies after liver transplantation. *Transplant Rev*. 2015; 29(1): 38-41. **(invited)**
27. **Pillai A**, Anania F, Pearlman B. Caution: Reactivation of Reactivation of hepatitis B during hepatitis C treatment with direct-acting antiviral therapy. *Am J Gastroenterol* 2016 Dec; 111: 1854-1856.
28. **Pillai A**. Mixed Hepatocellular-Cholangiocarcinoma: Is it Time to Rethink Consideration for Liver Transplantation? *Liver Transpl* 2018 Oct 24(10):1329-1330. **(invited)**
29. Couri T, **Pillai A**. Goals and targets for personalized therapy for HCC. *Hepatol Int*. 2019 Jan 1. doi: 10.1007/s12072-018-9919-1. **(invited)**

30. Mikolajczyk AE, Yassan LJ, **Pillai AA**. A Patient with an Elevated  $\alpha$ -fetoprotein level and Liver Masses. JAMA 2019 Jan1; 321(1)97-98.
31. Mikolajczyk AE, Yassan LJ, **Pillai AA**. Approach to Evaluation of Multiple Liver Lesions-Reply. JAMA. 2019;321(20)2031-2032.
32. **Pillai A**, Couri T, Charlton M. Liver Allocation Policies in the USA: Past, Present, and the Future. Dig Dis Sci. 2019 Apr 64(4): 985-992.
33. Cotter TG, **Pillai AA**. Consult for Portal Vein Thrombosis. Clinical Liver Disease. 2019 Sept 14(2): 74-77. <https://doi.org/10.1002/cld.748>. **(invited)**
34. Rana P, Haydek JP, **Pillai A**. The Current Landscape of Systemic Therapies for Advanced HCC. Current Hepatology Reports, 2019 Dec 18(4): 371-382. **(invited)**
35. Lin A, Alpert L, Hart J, Chapman C, **Pillai A**. Lymphoepithelioma-like carcinomas – a rare variant of cholangiocarcinoma. Hepatology July 2020; 72(1):353-355.
36. Ahmed O, Salaskar A, Zangan S, **Pillai A**, Baker T. Transsplenic portal vein recanalization and direct intrahepatic portosystemic shunt placement to optimize liver transplantation. CVIR Endovascular. 2020; 3(5): 1-4.
37. Parikh ND, **Pillai A**. PET/CT as a Diagnostic and Prognostic Biomarker for Hepatocellular Carcinoma – Ready for Primetime?, Liver Transplantation, 2020 April; 26(6):746-747. **(invited)**
38. Ahmed O, **Pillai A**. Hepatocellular Carcinoma – A Contemporary Approach to Locoregional Therapy. Am J Gastroenterol. 2020 Nov; 115(11);1733-1736
39. **Pillai A**, Ahn JA, Kulik L. Integrating genomics into clinical practice in hepatocellular carcinoma – the challenges ahead. Am J Gastroenterol. 2020 Dec; 115(12): 1960-1969.
40. **Pillai A**, Ramanathan M, Kulik L. Locoregional Therapies for Hepatocellular Carcinoma: What has Changed in the Past Ten Years?. Clin Liver Dis. 2020 Nov; 24(4): 681-700.
41. Ferrante N, **Pillai A**, Singal A. Update on the Diagnosis and Treatment of Hepatocellular Carcinoma, Gastroenterology and Hepatology. 2020 Oct; 16 (10): 506-516.
42. Patel P, Wang J, **Pillai A**. Con: Patients with alcoholic hepatitis should not be considered for transplant, Clinical Liver Disease 2020 Dec; doi:10.1002/cld.937
43. Wang J, **Pillai A**. Systemic Therapy for HCC, Clinical Liver Disease; doi: 10.1002/cld.1058
44. Aitchison G, **Pillai A**, Dahman B, John B. Recent Advances in Systemic Therapies for Advanced Hepatocellular Carcinoma, Current Hepatology Reports 2021 Feb; doi: 10.1007/s11901-021-00560-2
45. Hutchison A, **Pillai A**. COVID-19: Impact on Liver Transplantation, Curr Opin Organ Transplant, 2021 June; 26(3): 339-345 **(invited)**

Case Reports:

46. Cohen SM, Heywood E, **Pillai A**, Ahn J. Hepatotoxicity Associated with the Use of White Flood, a Nutritional Supplement. *Practical Gastroenterology*. 2012 Oct; 36 (10): 45-47.
47. Huguenard AL, Nair K, **Pillai A**. Obscure Gastrointestinal Bleeding in the Setting of Portal Hypertension. *J Clin Gastroenterol*, 2016 (Jan), Vol 50 (1): 92-93.
48. Couri T, Harmath C, Baker T, **Pillai A**. Acute portal vein thrombosis after liver transplant presenting with acute abnormalities: A case report and literature review. *World J Hepatol*. 2019 Feb 27; 11(2): 234-241.

Book Chapters:

49. **Pillai A**, Ahn JA, Cohen SM. Resect or observe asymptomatic hepatic adenoma. In: *Controversies in Hepatology: The Experts Analyze Both Sides*. Jensen DM, ed. Slack Incorporated. Thorofare, NJ. 2011, Chapter 10: 93-99.
50. **Pillai A**, Fimmel CJ. Emerging diagnostics: genetics and biomarkers. In: *Primary Liver Cancer: Surveillance, Diagnosis and Treatment*. Reau N and Poordad F, ed. Springer Science & Business Media, Inc. 2012, Chapter 13: 247-262.
51. Robertazzi S, **Pillai A**. Extrahepatic manifestations in hepatitis C. In: *Hepatitis C*. Reau N and Jensen D, ed. Oxford University Press, Inc. 2013, 1<sup>st</sup> edition, Chapter 8: 63-70. **(invited)**
52. Dbouk N, **Pillai A**, Mendel B, et al. Liver. In: *Sleisenger and Fordtran's Gastrointestinal and Liver Disease Review and Assessment*. Qayed E, Srinivasan S and Shahnava N, ed. Saunders, Elsevier, Inc. 2016, 10<sup>th</sup> Edition, Chapter 9: 171-242. **(invited)**
53. Wang X, **Pillai A**. Extrahepatic manifestations of Chronic Hepatitis C Infection: a Review and Update. In: *Current Hepatology Reports*. Ahn J, Bacon B and Reddy R, ed. 2016, Vol 15 (3). DOI 10.1007/s11901-016-0309-7. **(invited)**
54. Robertazzi S, **Pillai A**. Extrahepatic manifestations in hepatitis C. In: *The New Hepatitis C*. Reau N and Jensen D, ed. Oxford University Press, Inc. 2018, 2<sup>nd</sup> edition, Chapter 8: 75-82. **(invited)**
55. **Pillai A**, Friedman LS. Viral Hepatitis. In: *Sitaraman and Friedman's Essentials of Gastroenterology*. Srinivasan S, Friedman L, Anania F, ed. John Wiley and Sons, Ltd. 2018, 2<sup>nd</sup> edition, Chapter 13: 195-210. **(invited)**
56. Norvell JP, **Pillai A**, Flynn M. Gastrointestinal and Hepatic Physiology in Liver Disease, In: *Hepatic Critical Care*. Nanchal R and Subramanian R, ed. Springer Science & Business Media, Inc. 2018, Chapter 4: 45-51.
57. **Pillai A**, Couri T. General Overview of the Liver Transplant Patient. In: *Liver Disease: A Clinical Casebook*. Cohen, SM and Davitkov P, ed. Springer Science & Business Media, Inc. 2018, Chapter 19: 255-277. **(invited)**

58. Singal A, Parikh N, Rich N, John B, **Pillai A**. Hepatocellular Carcinoma Surveillance and Staging. In: Hepatocellular Carcinoma: Translational Precision Medicine Approaches. Hoshida Y, ed. Springer Science & Business Media, Inc. 2019, 27-51.
59. \*Wang J, **Pillai A**. Local regional therapy in combination with systemic therapy offers an advantage over either modality alone. Controversies in Hepatocellular Carcinoma. Reau N and Singal A, ed, Slack Inc, 2020, **accepted**, *\*pending publication (invited)*

Other works that are publically available:

1. Overview of Liver Transplantation. Practical Gastro Live (live podcast on [intimetv.com](http://intimetv.com)), 3/20/10
2. Living Healthy Chicago: Acute Fatty Liver of Pregnancy, 12/11/2011 (date aired)
3. Univision: Alcoholic Liver Disease, 2/5/2012 (date aired)
4. Commentary as HCV expert, article published in Georgia Health News on 5/6/14.  
<http://www.georgiahealthnews.com/2014/05/hepatitis-c-high-cost-cure/#more-31521>
5. Discussion on hepatitis B&C, Sagal Radio Show, 10/9/15  
<http://www.sagalradio.org/articles/2015/10/10/discussion-hepatitis-b-c-diseases-can-have-detrimental-effects-if-left-un-treated#.VhmLYPIVhBd>
6. American Liver Foundation: Wellness Webinars – Focusing on Your Health While Combating Chronic Liver Disease 2/14/18. [https://urldefense.proofpoint.com/v2/url?u=https-3A\\_youtu.be\\_Tuld-5FVWDdx8&d=DwIFAg&c=Nd1gv\\_ZWYNIRyZYzmXb18oVfc3ITqv2smA\\_esABG70U&r=KTJVti3akSWIBVKmdkn8Vjt5Dyf\\_5PzoXgOttAMOWDy\\_vvh4fmCzXKyFMXwq2CnX&m=m4jsWQ2XuMTU77uYe4RkGi7KzJ9csqJWhYELzldvEg0&s=tTQ8yk9waknS7Vpj3Nf6OABj00iDW9nQ2p1Cf\\_OWYdg&e=](https://urldefense.proofpoint.com/v2/url?u=https-3A_youtu.be_Tuld-5FVWDdx8&d=DwIFAg&c=Nd1gv_ZWYNIRyZYzmXb18oVfc3ITqv2smA_esABG70U&r=KTJVti3akSWIBVKmdkn8Vjt5Dyf_5PzoXgOttAMOWDy_vvh4fmCzXKyFMXwq2CnX&m=m4jsWQ2XuMTU77uYe4RkGi7KzJ9csqJWhYELzldvEg0&s=tTQ8yk9waknS7Vpj3Nf6OABj00iDW9nQ2p1Cf_OWYdg&e=)
7. Commentary on policy change for alcoholic hepatitis, article published in the Chicago Tribune on 3/4/18. <http://www.chicagotribune.com/business/ct-biz-liver-transplant-sober-policy-0304-story.html>
8. Facebook Live -At the Forefront: Hepatocellular Carcioma, University of Chicago Medicine, 8/2/19
9. Consult for Portal Vein Thrombus. Clinical Liver Disease. August 2019.  
<https://aasldpubs.onlinelibrary.wiley.com/hub/journal/20462484/video/14-2-interview-pillai>
10. Onclive coverage HCC-TAG. March 1, 2020. <https://www.onclive.com/conference-coverage/hcc-tag-2020/pillai-reflects-on-achieved-goals-at-inaugural-hcctag-conference>
11. Evaluating Current Changes in HCC. May 7, 2020. <https://www.targetedonc.com/view/evaluating-current-challenges-in-hepatocellular-carcinoma>
12. Facebook Live – At the Forefront: Innovating Liver Cancer Treatment, U of Chicago, 1/27/21
13. Commentary on policy changes for alcoholic hepatitis, interviewed by Target 8. Aired 3/4/21.  
<https://www.woodtv.com/news/target-8/live-or-let-die-transplants-only-option-as-more-suffer-alcohol-induced-liver-failure/>
14. Onclive Coverage HCC-TAG. March 19, 21. <https://www.onclive.com/view/hcc-tag-conference-to-highlight-headway-made-in-hcc-care-amidst-covid-19-pandemic>
15. Interview for Liver Fellow Network, aired 5/3/21. <https://liverfellow.org/post/talking-with-dr-anjana-pillai-about-liver-cancer-and-navigating-early-career>

**INVITED SPEAKING**

a. International:

1. 2021 Immune Phenotype and Check point inhibitors for the treatment of HCC, Asian Pacific Association for the Study of the Liver (APASL), **annual meeting**, Singapore, (virtual), 2/4/21
2. 2021 Liver Cancer Surveillance and Treatment Options, University of Chicago Global Clinical Webinar Series (virtual- seen by international providers in 21 countries ), 2/24/21



3. 2021 *Beyond Size and Number – LT for HCC Beyond Milan, International Liver Transplant Societ, (virtual), 7/1/21*

b. National:

1. 2012 Nonalcoholic Steatohepatitis. Association of Kerala Medical Graduates (AKMG), **annual meeting**, Detroit, MI, 7/14/12
2. 2012 Current Treatments for Chronic HCV: Translating Clinical Studies into Clinical Practice. Creighton U Medical Center, Omaha, NE, 7/17/12
3. 2013 Chronic Hepatitis: Current Treatment and Implications for Morbidity and Mortality. American Council of Life Insurers: **annual meeting**, Atlanta, GA, 2/25/13
4. 2013 Hepatitis C Management Considerations in Challenging Patient Populations. Simply Speaking Hepatitis (CME), Digestive Specialists, Inc., Dayton, OH, 11/7/13
5. 2014 General Medicine Practices for Hepatitis B. Simply Speaking Hepatitis (CME), Orlando, FL 11/20/14
6. 2015 AASLD 2014 HCV Post Conference Update. Simply Speaking Hepatitis (CME), Washington DC, 2/11/15
7. 2015 New and Emerging Strategies to Simplify the cure of Chronic Hepatitis C Infection. Simply Speaking Hepatitis (CME), Anderson, South Carolina, 4/2/15
8. 2015 Alcoholic liver disease and Non-alcoholic steatohepatitis: Myth and Reality. American Association of Physicians of Indian Origin (AAPI), **annual meeting**, Orlando, FL 6/20/15
9. 2016 Prospects for Liver Cancer Screening. Dialogue for Action, Progress and Prospects in Cancer Screening and Prevention, **annual meeting**, Baltimore, MD, 4/7/16
10. 2017 HCV treatment for everyone?, Simply Speaking Hepatitis (CME). Michigan State University CME lecture series, Detroit, MI 5/20/17
11. 2017 Advances in HCC Therapy: The Emerging Role of Genomics in HCC, **annual meeting**, American Association for the Study of Liver Diseases (AASLD), Washington DC 10/21/17
12. 2017 SARA and SIRveNIB: What does this mean for Y90?, **annual meeting**, Advancer's Users – Interventional Radiology, Chicago, IL 11/16/17
13. 2017 Hepatologist's Viewpoint: Cirrhosis vs HCC Management Selection and Treatment Timing, **annual meeting**, Advanced Users -Interventional Radiology, Chicago, IL 11/17/17
14. 2018 Approach to Liver Lesions, **annual meeting**, American College of Gastroenterology (ACG) 2<sup>nd</sup> year Fellows Course, Washington DC, 1/14/18
15. 2018 Essentials in HCV: Best Practices Before and After the Cure, Simply Speaking Hepatitis (CME). Memphis, TN 10/24/18
16. 2018 HCC Management: Updates in AASLD guidelines and new systemic therapies 2018, **annual meeting**, Advanced Users - Interventional Radiology, Chicago, IL 11/16/18
17. 2019 Approach to Liver Lesions, **annual meeting**, ACG 2<sup>nd</sup> year Fellows Course, Washington DC 1/20/19
18. 2019 Essentials in HCV: Best Practices Before and After Cure, ID department, University of Minnesota, Simply Speaking Hepatitis (CME). Minneapolis, MN, 2/21/19
19. 2019 Making the Case for Liver Cancer Screening. Dialogue for Action, Progress and Prospects in Cancer Screening and Prevention, **annual meeting**, Baltimore, MD, 4/25/19
20. 2019 HCC: Multidisciplinary Liver Tumor Board, Society of Interventional Radiology, **annual fellows meeting**, 5/16/19
21. 2019 HCC: Multidisciplinary Approach to Care, AGA Post Graduate Course, **annual**

- meeting**, Digestive Diseases Week (DDW), San Diego, CA 5/18/19
22. 2019 Management of Post Transplant Patients with Recurrence, **annual meeting**, American Transplant Congress (ATC), Boston, MA 6/3/19
  23. 2020 Approach to Liver Lesions, **annual meeting**, ACG 2<sup>nd</sup> year Fellows Course, Washington DC 1/19/20
  24. 2020 Optimal Models for the Practice of Multidisciplinary Care, annual meeting, HCC-TAG, Park City, Utah 2/29/20
  25. 2020 Challenging Cases Related to Transplant Candidate Selection, Donor Selection, and Initial Immunosuppression (case-based presentations), **annual meeting**, AST Fellows Symposium on Transplantation, 9/24/20 (Virtual Live)
  26. 2020 Management of Post-Transplant Complications (case-based presentations), Transplant Immunology Boot Camp II, **annual meeting**, AST Fellows Symposium on Transplantation, 9/25/20 (Virtual Live)
  27. 2020 First Steps in HCV Elimination: Improved Screening and Linkage-to-Care Approaches, Simply Speaking Hepatitis (CME), Jacksonville, FL (Virtual) 10/27/20
  28. 2020 Update on Liver Transplantation and HCC for the Busy Gastroenterologist. HCC Primer, **annual meeting**, American College of Gastroenterology, Nashville, TN 10/28/20 (Virtual)
  29. 2021 AASLD Clinical Practice SIG Case Conference -Budd Chiari, Expert Discussant, 3/10/21 (Virtual)
  30. 2021 The Year in Review, HCC Therapeutic Agents (HCC-TAG), **annual meeting**, 3/26/21 (virtual)
  31. 2021 *First Steps in HCV Elimination: Improved Screening and Linkage-to-Care Approaches, Simply Speaking Hepatitis (CME), Reidsville, NC (Virtual), 6/3/21*

c. Regional \*(both Chicago and Atlanta included due to re-location)

1. 2010 Exploring liver disease: Town Hall meeting. American Liver Foundation, Chicago Chapter, Loyola University Medical Center, Chicago, IL, 5/15/10
2. 2011 Overview of liver transplantation. Internal Medicine Grand Rounds: Gottlieb Memorial Hospital, Chicago, IL, 8/15/11
3. 2011 Acute Liver Failure. Gastroenterology clinical conference, invited lecture, The University of Chicago Medicine, Chicago, IL, 8/25/11
4. 2013 Nonalcoholic steatohepatitis: An Update. Northern division of Georgia SGNA seminar, Atlanta, GA, 3/9/13
5. 2013 Update on hepatitis B and C. The 38<sup>th</sup> Annual Comprehensive Board Review in Internal Medicine (sponsored by Emory University SOM), Atlanta, GA, 7/27/13
6. 2013 New and Emerging Strategies to Simplify the Cure of Chronic HCV infection. Simply Speaking Hepatitis (CME), Chicago, IL, 10/15/13
7. 2014 Acute hepatitis. The 39<sup>th</sup> Annual Comprehensive Board Review in Internal Medicine (sponsored by Emory University SOM), Atlanta, GA, 7/26/14
8. 2014 Hepatitis C: an Update. International Transplant Nurses Society, Georgia chapter, Atlanta, GA, 9/9/14
9. 2015 Future Directions for Finding a Cure or Loss of HBsAg, Simply Speaking Hepatitis (CME), Chicago, IL 4/29/15
10. 2015 HCV Screening and Linkage to Care: The First Step to a Cure, Simply Speaking Hepatitis (CME). Athens, GA 5/12/15
11. 2015 Acute hepatitis. The 40<sup>th</sup> Annual Comprehensive Board Review in Internal Medicine (sponsored by Emory University SOM), Atlanta, GA, 7/25/15
12. 2015 A Multidisciplinary Approach to the Treatment and Diagnosis of Hepatocellular

- Carcinoma. Georgia Gastroenterologic and Endoscopic Society, annual meeting, Atlanta, GA, 9/12/15
13. 2015 Update on Liver Transplantation. Georgia Transplant Foundation - Trends in Transplant, regional meeting, Atlanta, GA 10/24/15
  14. 2016 HCC: Risk factors, surveillance and the importance of a multidisciplinary team; Gastroenterology clinical conference, invited lecture, The University of Chicago Medicine, Chicago, IL, 1/29/16
  15. 2016 HCV Screening and Linkage to Care: The First Step to a Cure, Simply Speaking Hepatitis (CME). Braselton, GA 6/7/16
  16. 2016 Chronic HCV Treatment Guidelines, Simply Speaking Hepatitis (CME). Taiwanese Medical Association, Southeast Chapter, Atlanta, GA 9/10/16
  17. 2017 Current Clinical Controversies in HCV Care, Simply Speaking Hepatitis (CME). Chicago, IL 5/23/17
  18. 2017 Update on HCC, Ask the Experts Forum, American Liver Foundation – Great Lakes Division, Chicago, IL 10/10/17
  19. 2018 Biomarkers and Drugs in Development, At the Forefront of Hepatology, University of Chicago Medicine CME, Chicago IL, 5/5/18
  20. 2018 Update on Management of Liver Tumors, Annual Updates in Digestive Diseases Meets Acing the GI Board Exam (sponsored by University of Chicago Digestive Diseases Center), Chicago, IL, 8/25/18
  21. 2018 HCC: Updates in Systemic Therapy, Western Suburbs Gut Club, Chicago, IL 10/23/18
  22. 2018 Essentials in HCV: Best Practices Before and After the Cure, American Philippine Medical Association, Simply Speaking Hepatitis (CME). Chicago, IL 11/4/18
  23. 2018 Liver Transplant for Hepatic Malignancies – Hepatology Perspective. Wellness House Liver Symposium, Hinsdale, IL 11/27/18
  24. 2019 Transplant Pearls for the Primary Care Physician, Internal Medicine Grand Rounds, NorthShore University Health System, Evanston, IL 1/18/19
  25. 2019 Female Hormones and Liver Tumors: Where is the Link? First Annual Women in GI: At the Forefront, University of Chicago Medicine CME, Chicago, IL 3/9/19
  26. 2019 Downstaging for HCC, At the Forefront of Hepatology, University of Chicago Medicine CME, Chicago, IL, 5/4/19
  27. 2019 HCV elimination in PWIDs and the Incarcerated, Simply Speaking Hepatitis (CME). Chicago, IL, 9/25/19
  28. 2019 HCC: Downstaging , American Liver Foundation: HCC LIVE, Chicago, IL 10/15/19
  29. 2020 Liver Cancer and Transplant During COVID 19: Systemic Therapy in Advanced HCC during COVID-19, sponsored by American Liver Foundation, Chicago, IL 8/20/20

## **INVITED, ELECTED, OR APPOINTED EXTRAMURAL SERVICE**

### a. National and International

#### *American Society of Transplantation*

- 2012-2014 HBV Donor Guidelines Committee (published guidelines in Am J Transpl, 2015)
- 2014-present Liver and Intestinal COP (LICOP) Education Sub-Committee
- 2019-2020 LICOP Executive Committee, Member-at-Large (elected 2 year term\*)  
\*transitioned to Co-Chair in 2020
- 2020-2022 Co-Chair, LICOP Education Sub-Committee (appointed 2 year term)
- 2020-2022 Co-chair, LICOP Executive Committee (elected 2 year term)

- 2021 Consensus Conference Co-Chair, Living Donor Liver Transplantation: A Multi Center/Society Collaboration Towards Growth and Consensus
- 2022-2024 Chair, LICOP Executive Committee (elected 2 year term)

*American College of Gastroenterology*

- 2016-present Practice Parameters Committee
  - 2018-2021 Hepatology Section Chair (appointed 3 year term)
- 2016-present Education Universe Editorial Board, Director of Hepatology (*appointed*)

*American Association for the Study of Liver Diseases*

- 2015-2018 CME Committee
- 2017-2018 AASLD/NBME Test-item workshop
- 2018-present AASLD Liver Transplantation and Surgery SIG, Education sub-committee
- 2019-2022 Practice Guidelines Committee
- 2020-present Fellow of the American Association for the Study of Liver Diseases

*American Gastroenterology Association*

- 2019-2022 GI Training Exam Sub-committee
  - 2020-2021 Hepatology section chair (*appointed term*)

*HCC Therapeutic Agents Conference (HCC TAG)*

- 2020-present Co-Founder and Director, annual national conference ([www.hcc-tag.org](http://www.hcc-tag.org))

*United Network of Organ Sharing (UNOS)*

- 2017-2019 Region 7 Liver Review Board Member
- 2019-present National Liver Review Board, Adult HCC Specialty Board

*Other*

- 2011-present Asian Health Foundation, National Advisory Board
- 2012-present Speaker's Bureau, Simply Speaking Hepatitis - CME conferences, by invitation only
- 2015 Steering Committee, Centers for Disease Control, HCV elimination in the Republic of Georgia (former USSR)
- 2018-present LI-RADS Management Working Group, Committee Member
  - Co-Lead of writing group
- 2019-present Chair of Resident/Young Faculty Networking Center and Steering Committee Member, Women in Medicine Summit, annual national conference

b. Regional

*American Liver Foundation, Great Lakes Division*

- 2010-2012 Medical Advisory Committee  
Mentor, Academic Debates, ('10\*, '11\*)
- 2017-present Medical Advisory Committee  
Mentor, Academic Debates ('19, '20\*) \*Competition Winner  
Competition Judge, Academic Debates ('21)

*Other*

- 2014-2016 Member, Georgia Cancer Coalition
- 2014-2016 Member, Georgia Viral Hepatitis Working Group

Manuscripts: Editorships and Editorial Boards

- 2016-present Clinical and Translational Gastroenterology (Editorial Board)
- 2018-2026 Liver Transplantation (Editorial Board)
- 2019-2021 Hepatology (Editorial Board)
- 2019-2020 Clinical Liver Disease (Guest Editor) – Liver manifestations of GI disorders

### Manuscripts: Ad-hoc Reviewer

Alimentary Pharmacology & Therapeutics, Hepatology, Liver Transplantation, American Journal of Transplantation, American Journal of Gastroenterology, Clinical and Translational Gastroenterology, Digestive Diseases and Sciences, World Journal of Gastroenterology, Clinical Transplantation, Annals of Hepatology, Journal of Clinical Gastroenterology, Transplantation, Liver International, Journal of Clinical Oncology, Clinical Liver Disease, Gastroenterology, British Medical Journal

### National Meeting Abstract Reviewer

2010-2012 Clinical Vignettes, American Transplant Congress  
2011-2012 Clinical Vignettes, American College of Gastroenterology  
2016-2020 Liver- HCC/Cholangio malignancies, American Transplant Congress  
2016-2020 Liver Abstracts, American College of Gastroenterology  
2019-present Liver Transplantation and Liver Surgery, AASLD  
2019-present International Liver Cancer Association, Annual Conference  
2019-present Hepatobiliary Neoplasia: HCC and Cholangiocarcinoma, Digestive Diseases Week  
2021-present Hepatobiliary Neoplasia, AASLD

### National Scientific Meeting Session Moderator

2018 American Association for the Study of Liver Diseases, San Francisco, CA. E-poster moderator for Liver Transplant and Surgery SIG, 11/11/18  
2019 American Transplant Congress, Boston, MA. The Changing Face of Cholangiocarcinoma, 6/5/19  
2019 American Association for the Study of Liver Diseases, Boston, MA. Parallel Session- Liver Transplant: Alcohol, HCC and Viral, 11/10/19  
2020 HCC Therapeutic Agents (HCC-TAG), Park City, Utah

- Treatment Interventions for HCC, 2/28/20
- Debates: Controversies in HCC, 2/29/20
- Oral Abstract Presentations 2/29/20

2020 American Transplant Congress, Philadelphia, PA (\*in person meeting cancelled due to COVID-19)

- Herding HCC into the Transplant Corral, 6/3/20
- Oral Abstract Session–HCC

2021 ACG Virtual Grand Rounds, Evaluation of Liver Masses 3/4/21  
2021 HCC Therapeutic Agents (HCC-TAG) – virtual, Debates: Controversies in HCC, 3/27/21  
2021 Digestive Diseases Week (virtual), Hepatobiliary Neoplasia, 5/21/21

### Other Moderator Sessions

2020 GI Journal Club (Twitter), 8/26/20, 5/26/21  
2020 Moderator for Women in Transplantation Webinar – Gender Inequality in the Time of COVID, 9/8/2020